30
/it/
AIzaSyAYiBZKx7MnpbEhh9jyipgxe19OcubqV5w
April 1, 2024
2135661
178559
2
Public Timelines FAQ
Public TimelinesFAQ
Public TimelinesFAQ
For educational institutions For teachers For students Open cabinet
For educational institutions For teachers For students Open cabinet
Creare
Create a timeline
Public timelines
Library
FAQ

10 magg 2013 anni - FDA responded to a petition and the original formulation of Opana ER (oxymorphone hydrochloride) Extended-Release Tablets was not withdrawn from the market for reasons of safety or effectiveness. As a result, generic versions of the original formulation can continue to be approved and marketed.

Aggiunto al nastro di tempo:

Opioids and the FDA

ByAnastasia
13 nov 2018

Data:

10 magg 2013 anni
Adesso
~ 11 years ago
About & FeedbackAccordoPrivatezzaBiblioteca
2024 © Time.Graphics
Support 24/7  
CabinetGet premium
Donate
The service accepts bank transfer (ACH, Wire) or cards (Visa, MasterCard, etc). Processed by Stripe.
Secured with SSL
Excellent (Trustpilot Reviews)
Based on 115+ reviews